ArticleNature genetics2018
Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
Open access · bronzeAbstract read
In one paragraph
Article in Nature genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers.
0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
204 citing papers in PubMed, 295 citations in OpenAlex.
- A core transcriptional regulatory circuitry controls super-enhancer-driven activation of LGR5 in colorectal cancer.Nature communications · 2026Article
- Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Decoding the mechanisms of cooperative DNA binding by the Paired-like homeodomain family.Nature communications · 2026Article
- The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches-A Narrative Review.Health science reports · 2026Article
- Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation.Molecular cancer research : MCR · 2026Article
- Core transcriptional regulatory circuitry identified from patient-derived tumor cells provides a specific vulnerability for rhabdomyosarcoma.Cell death & disease · 2026Article
- Alternative Splicing of the NF-Y Subunit, NF-YA, in Neuroblastoma Phenotype Heterogeneity.Cancers · 2026Review
- Regulation of PHOX2B gene expression by the long non-coding natural antisense RNA PHOX2B-AS1.The FEBS journal · 2026Article
- Neural crest gene regulatory networks as drivers of development, diversification and disease.Nature reviews. Molecular cell biology · 2026Review
- A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma.Clinical and translational science · 2026Article
- Article
- Multi‑omics identification of MSI2 as a super-enhancer‑driven vulnerability in MYCN‑amplified neuroblastoma.Journal of translational medicine · 2026Article
- MYCN Amplification Drives Ferroptosis Susceptibility via Cysteine Metabolism in Retinoblastoma.Investigative ophthalmology & visual science · 2026Article
- Reprogramming lipid metabolism in pediatric cancers.Oncogenesis · 2026Review
- Disruption of the SAGA CORE triggers collateral degradation of KAT2A.Nature communications · 2026Article
- Epigenetic Regulation of Trk Receptors and Neurotrophic Signalling in Neuroblastoma: Mechanisms, Plasticity, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma.Molecular cancer therapeutics · 2026Article
- Protease-mediated PRC1 dissociation promotes H2AK119ub remodeling during stress responses.The EMBO journal · 2026Article
- MYCN inhibits TrkC-mediated differentiation in neuroblastoma cells via disruption of the PKA signalling pathway.Cell death discovery · 2026Article
- Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma.Clinical and translational science · 2026Article
144 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Adam D DurbinDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5472-9847
Mark W ZimmermanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2489-3889
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5048-067X
Brian J AbrahamWhitehead Institute for Biomedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8085-3027
Amanda Balboni IniguezDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nina Weichert-LeaheyDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shuning HeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John M Krill-BurgerThe Broad Institute, Cambridge, MA, USA.
David E RootThe Broad Institute, Cambridge, MA, USA.
Francisca VazquezThe Broad Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2857-4685
Aviad TsherniakThe Broad Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3797-1877
William C HahnThe Broad Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2840-9791
Todd R GolubDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0113-2403
Richard A YoungWhitehead Institute for Biomedical Research, Cambridge, MA, USA. young@wi.mit.edu.ORCID http://orcid.org/0000-0001-8855-8647
A Thomas LookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. thomas_look@dfci.harvard.edu.
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. kimberly_stegmaier@dfci.harvard.edu.ORCID http://orcid.org/0000-0003-0218-7895
Broad Institute · USDana-Farber Cancer Institute · USWhitehead Institute for Biomedical Research · USBoston Children's Hospital · US
Funding
Research Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MIntegrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerR35CA210030 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2016 to 2022
$7.3MMechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in CancerR35CA210064 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2016 to 2022
$7.3MTranscriptional regulatory networks in living cellsR01GM123511 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI YOUNG, RICHARD · 2017 to 2020
$3.6MTargeting BET-bromodomains in neuroblastomaR01NS088355 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEGMAIER, KIMBERLY, WEISS, WILLIAM A · 2015 to 2019
$3.3MRole of LMO1 in Neuroblastoma Initiation and MaintenanceR01CA180692 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI LOOK, A. THOMAS, MARIS, JOHN M · 2015 to 2019
$3.0MHoward Hughes Medical InstituteNCI NIH HHS R01 CA180692NCI NIH HHS R35 CA210030NCI NIH HHS R35 CA210064NCI NIH HHS T32 CA136432NCI NIH HHS U01 CA176058NIGMS NIH HHS R01 GM123511NINDS NIH HHS R01 NS088355
Abstract
Childhood high-risk neuroblastomas with MYCN gene amplification are difficult to treat effectively
Indexed as
Gene Expression Regulation, NeoplasticTranscription, GeneticAnimalsCell Line, TumorCRISPR-Cas SystemsDisease Models, AnimalDown-RegulationFemaleGene AmplificationHumansMiceMice, NudeNeuroblastomaN-Myc Proto-Oncogene ProteinTranscription FactorsMYCN protein, humanN-Myc Proto-Oncogene ProteinTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.